Ann: Appendix 4C - quarterly, page-2

"Commentary: Cash receipts from customers continued to grow strongly during the period, resulting in
a 133% increase compared to the corresponding quarter in FY 2015 and up 105% on the previous
quarter. This growth almost exclusively stems from increased USCOM 1A sales.
Cash outflow was reduced from $412k to $345k, despite one off costs preparing the Uscom BP+ and
Thor products for market and an increase in personnel.
Cash on hand at the end of the quarter was up 35% to $1.57m following the $700k payment to purchase
Thor Laboratories and a capital raising totalling $2.14m.
International manufacturing strategies are being implemented to ensure uninterrupted supply of product
to meet the anticipated global demand for the Uscom range of devices. The new suites of Uscom BP+
and Uscom BP+Reporter and Thor, now rebranded as Uscom SpiroSonic pulmonary devices, will be
brought to market early in 2016."

but still not cash positive. but as all the growth in sales apparently relate to Uscom 1a then one would think there is substantial room for further growth. wouldn't have minded some breakdown of sales by area and product and some indication of the sept sales from the Thor products.